Vicore Pharma Holding AB (publ) (VCRE)
NASDAQ: VCRE · Real-Time Price · USD
11.35
-0.17 (-1.48%)
Aug 26, 2026, 4:00 PM EDT - Market closed
Vicore Pharma Holding AB Revenue
Vicore Pharma Holding AB had revenue of 2.21M SEK in the quarter ending June 30, 2026, with 26.75% growth. This brings the company's revenue in the last twelve months to 3.99M, down -48.40% year-over-year. In the year 2025, Vicore Pharma Holding AB had annual revenue of 3.82M, down -96.51%.
Revenue (ttm)
3.99M SEK
Revenue Growth
-48.40%
P/S Ratio
763.87
Revenue / Employee
99,850 SEK
Employees
40
Market Cap
314.78M USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.82M | -105.53M | -96.51% |
| Dec 31, 2024 | 109.35M | - | - |
| Dec 31, 2023 | 0 | - | - |
| Dec 31, 2022 | 0 | - | - |
| Dec 31, 2021 | 0 | - | - |
| Dec 31, 2020 | 0 | - | - |
| Dec 31, 2019 | 0 | - | - |
| Dec 31, 2018 | 508.00K | -424.00K | -45.49% |
| Dec 31, 2017 | 932.00K | 80.00K | 9.39% |
| Dec 31, 2016 | 852.00K | 12.00K | 1.43% |
| Dec 31, 2015 | 840.00K | -11.00K | -1.29% |
| Dec 31, 2014 | 851.00K | 131.00K | 18.19% |
| Dec 31, 2013 | 720.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Vanda Pharmaceuticals | 215.72M |
| Bicycle Therapeutics | 61.21M |
| Orchestra BioMed Holdings | 31.98M |
| ProQR Therapeutics | 21.05M |
| Fate Therapeutics | 6.49M |
| Cartesian Therapeutics | 1.48M |
| YD Bio | 510.36K |
| SAB Biotherapeutics | 114.70K |
VCRE News
- 14 hours ago - Vicore Pharma to Present at The Pareto Securities 17th Annual Healthcare Conference - Accesswire
- 1 day ago - Vicore Pharma Holding AB Slides: Corporate presentation - Filings
- 2 days ago - Vicore Pharma to Present at the European Respiratory Society Congress 2026 - Accesswire
- 5 days ago - Vicore Pharma Holding AB Quarterly report: Q2 2026 - Filings
- 7 weeks ago - Vicore Pharma to Participate in the Leerink Therapeutics Forum - Accesswire
- 2 months ago - Vicore Pharma Holding AB Transcript: Status update - Transcripts
- 2 months ago - Vicore Pharma Holding AB Press release: Status update - Filings
- 2 months ago - Vicore Pharma Holding AB Slides: Status update - Filings